Ranbaxy Laboratories has dipped nearly 6% at Rs 364 in early morning deals on BSE after reporting a consolidated net loss of Rs 454 crore for the third quarter ended September 2013 (Q3) due to forex loss. The pharmaceutical company had profit of Rs 754 crore in a year ago quarter.
The company incurred a forex charge of Rs 360 crore during the reported quarter, against forex gain of Rs 393 crore in the same period last year, Ranbaxy said in a statement.
The consolidated net sales also grew marginally by 3% at Rs 2,750 crore against Rs 2,670 crore in the corresponding quarter of previous year.
The company said sale impacted by the new pricing policy and trade concerns in India and the absence of any post exclusively sales during the quarter.
The company incurred a forex charge of Rs 360 crore during the reported quarter, against forex gain of Rs 393 crore in the same period last year, Ranbaxy said in a statement.
The consolidated net sales also grew marginally by 3% at Rs 2,750 crore against Rs 2,670 crore in the corresponding quarter of previous year.
The company said sale impacted by the new pricing policy and trade concerns in India and the absence of any post exclusively sales during the quarter.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%